Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Open-Label, Controlled Study of Romiplostim N01 Combined With All-Trans Retinoic Acid Versus Romiplostim N01 Alone for Persistent Isolated Chemotherapy-Induced Thrombocytopenia in Patients With Complete Remission of Gynecologic, Breast, or Lung Solid Tumors

NCT07586826 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT07586826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07586826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Open-Label, Controlled Study of Romiplostim N01 Combined With All-Trans Retinoic Acid Versus Romiplostim N01 Alone for Persistent Isolated Chemotherapy-Induced Thrombocytopenia in Patients With Complete Remission of Gynecologic, Breast, or Lung Solid Tumors
Lead sponsor
Peking University People's Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
December 22, 2025
Completion date
December 31, 2027
Enrollment
220 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, cervical cancer, chemotherapy-induced thrombocytopenia, fallopian tube cancer, gynecologic cancers, lung cancer, non-small cell lung cancer, ovarian cancer, persistent isolated chemotherapy-induced thrombocytopenia, primary peritoneal cancer